A carregar...
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death‐Ligand 1 Blockade: A Case Discussion and Review of the Literature
A breakthrough in oncology over the last 5 years, immunotherapy has proved its salutary effects in a wide range of solid tumors. The targeting of the programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) pathway can restore a competent antitumor T‐cell response by addressing key t...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216449/ https://ncbi.nlm.nih.gov/pubmed/32091646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0671 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|